

April 30, 2009

To Whom It May Concern

Company: Taisho Pharmaceutical Co., Ltd.
Representative: Akira Uehara, CEO
(First Section of TSE: Code 4535)
Contact: Masaki Tsuboi, General Manager,
Public Relations Section
(Tel: +81-3-3985-1115)

Notice of Revisions to Fiscal 2008 Full-year Forecasts

Taisho Pharmaceutical Co., Ltd. has revised its full-year forecasts for fiscal 2008, the year ended March 31, 2009, which were announced on January 29, 2009. These revisions were made in light of recent business performance and other factors. Details are as follows.

1. Consolidated Forecasts of Business Results

(Millions of yen, %)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A)	255,000	36,500	37,500	6,500
Revised Forecast (B)	256,200	37,900	39,900	8,800
Change (B-A)	1,200	1,400	2,400	2,300
Change (%)	0.5	3.8	6.4	35.4
Fiscal 2007 Full Year	249,655	36,952	41,896	25,004

2. Non-consolidated Forecasts of Business Results

(Millions of yen, %)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A)	198,000	31,500	38,000	10,500
Revised Forecast (B)	198,800	32,000	38,900	11,800
Change (B-A)	800	500	900	1,300
Change (%)	0.4	1.6	2.4	12.4
Fiscal 2007 Full Year	201,665	34,207	40,122	25,910

3. Reasons for Revisions

Taisho Pharmaceutical expects fiscal 2008 net sales to slightly outperform the previous forecast mainly thanks to steady growth in prescription pharmaceutical sales centered on antibacterial agents.

In addition, Taisho Pharmaceutical has raised its forecasts for operating income, ordinary income and net income. These revisions are mainly based on projected lower costs, particularly advertising and sales promotion expenses, as well as better-than-anticipated non-operating income and expenses, and a review of income taxes.

Note: The above forecasts were formulated based on information available as of the release date of this report. A number of subsequent factors may cause actual results to differ materially from these forecasts.